Table 1 Patient demographic and baseline characteristics (randomized patients population)
Characteristic | Saxagliptin + Metformin (n = 74) | Placebo + Metformin (n = 86) |
|---|---|---|
Men, n(%) | 40 (54.1) | 45 (52.3) |
Mean (SD) age, y | 53.9 (10.35) | 56.6 (9.97) |
Race, n(%) | Â | Â |
   White | 64 (86.5) | 80 (93.0) |
   Black/African American | 8 (10.8) | 3 (3.5) |
   American Indian or Alaska native | 0 | 1 (1.2) |
   Asian | 2 (2.7) | 2 (2.3) |
Ethnicity, n(%) | Â | Â |
   Hispanic or Latino | 29 (39.2) | 35 (40.7) |
   Not Hispanic or Latino | 34 (45.9) | 36 (41.9) |
   Not reported | 11 (14.9) | 15 (17.4) |
BMI, kg/m2 | Â | Â |
   Mean (SD) | 33.7 (5.94) | 32.5 (6.18) |
   Median (range) | 33.8 (19.89–44.95) | 31.1 (20.68–44.64) |
Mean (SD) duration of type 2 diabetes, y | 5.8 (6.37) | 6.2 (4.21) |
Mean (SD) HbA1c,% | 7.92 (0.961) | 7.97 (0.819) |
Mean (SD) FPG, mg/dL | 164.9 (47.16) | 161.5 (41.71) |
Metformin dose (mg), n(%) | Â | Â |
   1500– <2000 | 28 (37.8) | 35 (40.7) |
   2000– <2500 | 38 (51.4) | 45 (52.3) |
   ≥2500 | 8 (10.8) | 6 (7.0) |